BASES MOLECULARES DE LA ESQUIZOFRENIA
443
20.
Owen, M.J.; Craddock, N. & O'Donovan, M. C. (2005) Schizophrenia: genes at last? Trends
in Genetics 21, 518-‐525.
21.
Niemi, L. T.; Suvisaari, J. M.; Tuulio-‐Henriksson, A. & Lönnqvist, J. K. (2003) Childhood
developmental abnormalities in schizophrenia: evidence from high-‐risk studies.
Schizophrenia Research 60, 239-‐258.
22.
Snyder, S. H. (2006) Dopamine receptor excess and mouse madness. Neuron 49, 484-‐485.
23.
Carlsson, A. (1988) The current status of the dopamine hypothesis of schizophrenia.
Neurospsychopharmacology. 1, 179-‐186.
24.
Javitt, D. C. (1987) Negative schizophrenic syntomatology and the PCP (phencyclidine)
model of schizophrenia. Hillside Journal of Clinical Psychiatry 9, 12-‐35.
25.
Lang, U. E.; Puls, I.; Müller, D. J.; Strutz-‐Seebohm, N. & Galliant, J. (2007) Molecular
mechanisms of schizophrenia. Cellular Physiology and Biochemistry 20, 687-‐702).
26.
Javitt, D. C. & Zukin, S. R. (1991) Recent advances in the phencyclidine model of
schizophrenia. American Journal of Psychiatry 148, 1301-‐1308.
27.
Javitt, D.C. (2007) Glutamate and schizophrenia: phencyclidine, N-‐methyl-‐D-‐aspartate
receptors, and dopamine-‐glutamate interactions. International Review of Neurobiology
78, 69-‐108.
28.
Lindsley C. W.; Shipe W. D.; Wolkenberg S. E.; Theberge C. R.; Williams, D. L.; Sur, C. &
Kinney G. G. (2006) Progress towards validating the NMDA receptor hypofunction
hypothesis of schizophrenia. Current Topics in Medical Chemistry 6, 771-‐785.
29.
Watis, L.; Chen S. H.; Chua, H. C.; Chong, S. A. & Sim, K. (2008) Glutamatergic abnormalities
of the thalamus in schizophrenia: a systematic review Journal of Neural Transmission
115, 493-‐511.
30.
Millan, M. J. (2005) N-‐methyl-‐D-‐aspartate receptors as a target for improved antipsychotic
agents: novel insights and clinical perspectives. Psychopharmacology 179, 30-‐53.
31.
Olney, J. W.; Newcomer, J. W. & Farber, N. B. (1999): NMDA receptor hypofunction model
of schizophrenia. Journal of Psychiatry Research 33, 523-‐533.
32.
Moghaddam, B. (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron
40, 881-‐884.
33.
Goldstein, M. & Deutch, A. Y. (1992) Dopaminergic mechanisms in the pathogenesis of
schizophrenia. FASEB Journal 6, 2413-‐2421.
34.
Javitt, D. C.; Sershen, H.; Hashim, A. & Lajtha, A. (2000) Inhibition of striatal dopamine
release by glycine and glycyldodecylamide. Brain Research Bulletin 52, 213-‐216.
35.
Javitt, D. C. (2004) Glutamate as a therapeutic target in psychiatric disorders Molecular
Psychiatry 9, 984-‐997.
36.
Lechner, S. M. (2006) Glutamate-‐based therapeutic approaches: inhibitors of glycine
transport. Current Opinion on Pharmacology. 6, 75-‐81.
37.
Thomsen, C. (2006) Glycine transporter inhibitors as novel antipsychotics. Drug
Discovery: Therapeutic Strategies 3, 539-‐545.
38.
Lindsley, C. W.; Shipe, W. D.; Wolkenberg, S. E.; Theberge, C.R.; Williams, D. L. Jr.; Sur. C. &
Kinney, G. G. (2006) Progress towards validating the NMDA receptor hypofunction
hypothesis of schizophrenia. Current Topics in Medicinal Chemistry 6, 771-‐785.
39.
Descarries, L.; Bérubé-‐Carrière, N.; Riad, M.; Bo, G. D.; Méndez, J. A. & Trudeau, L. E. (2007)
Glutamate in dopamine neurons: synaptic versus diffuse transmission. Brain Research
Reviews 58, 290-‐302.
40.
Millan, M. J. (2005) N-‐Methyl-‐D-‐aspartate receptors as a target for improved antipsychotic
agents: novel insights and clinical perspectives. Psychopharmacology (Berlin) 179, 30-‐53.
